Peptides in Gastroenterology

Overview

The gastrointestinal (GI) tract is one of the largest endocrine organs in the body, producing dozens of peptide hormones that regulate digestion, nutrient absorption, motility, secretion, mucosal integrity, and appetite. Gastroenterology has been profoundly shaped by peptide biology — from the discovery of secretin in 1902 (the first hormone ever identified) to the modern era of GLP-1 receptor agonists and investigational repair peptides.

This article surveys the landscape of peptides relevant to gastrointestinal research, encompassing both well-characterized endogenous gut hormones and investigational compounds under study for GI conditions.

Endogenous GI Peptide Hormones

The gut produces a diverse array of regulatory peptides, each with distinct roles in digestive physiology:

Gastric Peptides

Gastrin is produced by G-cells of the gastric antrum and duodenum in response to stomach distension, vagal stimulation, and amino acid presence. Gastrin stimulates hydrochloric acid secretion from parietal cells, promotes gastric mucosal growth, and enhances gastric motility. Hypergastrinemia — chronically elevated gastrin — is associated with conditions such as Zollinger-Ellison syndrome and can be iatrogenically induced by proton pump inhibitor therapy.

Ghrelin is primarily produced by oxyntic cells of the gastric fundus and acts as both a hunger signal and a gastric prokinetic agent. Beyond its role in appetite regulation and GH release, ghrelin stimulates gastric acid secretion, enhances gastric emptying, and promotes small intestinal motility through vagal and enteric nervous system pathways.

Small Intestinal Peptides

Secretin is released by S-cells of the duodenum in response to acidic chyme entering the small intestine. It stimulates pancreatic bicarbonate secretion to neutralize gastric acid, inhibits gastric acid production, and promotes bile secretion from the liver. Secretin stimulation testing remains a diagnostic tool for evaluating exocrine pancreatic function and gastrinomas.

Cholecystokinin (CCK) is released by I-cells of the duodenum and jejunum in response to fatty acids and amino acids. CCK stimulates gallbladder contraction, pancreatic enzyme secretion, and satiety signaling. It acts through CCK-A receptors in the GI tract and CCK-B receptors in the brain.

GLP-1 and GLP-2 — Glucagon-like peptide-1, discussed extensively in GLP-1 receptor signaling, slows gastric emptying and reduces appetite. GLP-2, co-secreted from the same intestinal L-cells, is a potent intestinotrophic factor that promotes mucosal growth, enhances nutrient absorption, and reduces intestinal permeability. Teduglutide, a DPP-IV-resistant GLP-2 analog, is approved for the treatment of short bowel syndrome.

VIP (vasoactive intestinal peptide) is a neuropeptide found throughout the enteric nervous system that promotes intestinal water and electrolyte secretion, relaxes smooth muscle, and modulates immune function in the gut wall.

Colonic Peptides

Peptide YY (PYY) is released by L-cells of the ileum and colon postprandially. PYY(3-36), the predominant circulating form, acts on hypothalamic Y2 receptors to inhibit appetite and on GI receptors to slow gastric emptying and colonic transit — a component of the "ileal brake" mechanism that slows proximal GI transit when nutrients reach the distal gut.

Therapeutic GI Peptides

GLP-1 Receptor Agonists in GI Medicine

While developed primarily for type 2 diabetes and obesity, GLP-1 receptor agonists have significant GI implications:

• Gastric emptying delay — a therapeutically useful effect for postprandial glucose control but a potential concern in patients with pre-existing gastroparesis
• Nausea and vomiting — the most common side effects of GLP-1 agonists, mediated through area postrema and brainstem GLP-1 receptors. These effects typically diminish with continued use and dose titration
• Potential gastroparesis exacerbation — ongoing evaluation of GLP-1 agonist effects on gastric motility in susceptible populations
• Intestinal motility effects — reduced small bowel transit may contribute to constipation reported in some users

Linaclotide and Guanylate Cyclase-C Agonists

Linaclotide is a 14-amino-acid peptide that activates guanylate cyclase-C (GC-C) receptors on the luminal surface of intestinal epithelial cells. This stimulates chloride and bicarbonate secretion into the intestinal lumen, drawing water osmotically and accelerating colonic transit. Linaclotide is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Its minimal systemic absorption (acting almost entirely within the gut lumen) provides a favorable side effect profile.

Octreotide and Somatostatin Analogs

Octreotide and lanreotide are synthetic analogs of somatostatin used in gastroenterology for:

• Variceal hemorrhage (reducing portal blood flow)
• Secretory diarrhea (inhibiting intestinal secretion)
• Dumping syndrome (slowing gastric emptying and nutrient absorption)
• Carcinoid syndrome (suppressing serotonin and other mediators from neuroendocrine tumors)
• Pancreatic fistula management

Investigational Peptides in GI Research

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid fragment derived from human gastric juice protein. It is one of the most actively studied investigational peptides in gastrointestinal research. Preclinical studies (predominantly in rodent models) have reported:

• Accelerated healing of gastric ulcers, duodenal ulcers, and esophageal lesions
• Protection against NSAID-induced gastropathy
• Improved healing of inflammatory bowel disease-like lesions
• Enhanced intestinal anastomosis healing after surgical resection
• Cytoprotective effects on intestinal mucosa

BPC-157's proposed mechanisms include promotion of angiogenesis through VEGF upregulation, modulation of the nitric oxide system, and interaction with the dopaminergic system. However, it is important to note that clinical trial data in humans remains limited, and the compound has not received regulatory approval for any indication.

Gut-Brain Axis Peptides

The bidirectional communication between the GI tract and the central nervous system — the gut-brain axis — is heavily mediated by peptide signaling. Ongoing research is investigating how gut peptides (GLP-1, PYY, CCK, ghrelin) influence mood, cognition, and behavior, and conversely how centrally acting neuropeptides affect GI function. This intersection is particularly relevant to functional GI disorders such as irritable bowel syndrome, where altered gut-brain peptide signaling may contribute to visceral hypersensitivity and dysmotility.

Microbiome-Peptide Interactions

The gut microbiome influences and is influenced by GI peptide signaling. Microbial metabolites (short-chain fatty acids, secondary bile acids) stimulate enteroendocrine cells to release peptide hormones. Conversely, antimicrobial peptides such as defensins and LL-37 produced by intestinal Paneth cells help shape the composition of the gut microbiota. This bidirectional relationship is an active area of investigation.

Future Directions

Emerging areas of GI peptide research include:

• Dual and triple incretin agonists — compounds like tirzepatide (GIP/GLP-1) and retatrutide (GIP/GLP-1/glucagon) with combined metabolic and GI effects
• Targeted mucosal delivery — oral peptide formulations that deliver bioactive compounds directly to the intestinal mucosa
• Peptide-based diagnostics — gut peptide biomarker panels for early detection of GI malignancies and functional disorders
• Enteroendocrine cell biology — understanding how to modulate gut peptide secretion through dietary, pharmacological, and microbial interventions

Related Topics

• BPC-157 — investigational gastric peptide
• GLP-1 Receptor Signaling — incretin pathway with major GI effects
• Cholecystokinin — gallbladder and pancreatic stimulatory peptide
• Microbiome and Peptides — microbial interactions with gut peptide signaling
• Gut Healing Protocol — research protocol framework for GI peptides